Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM336 as Bridging Therapy Before CAR-T in RRMM
NCT07407010Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2026
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of gamgertamig in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Overall Response Rate and Safety and Tolerability. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
gamgertamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07407010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07407010.